Modifying the core structure of CDK9 inhibitors resolves efficacy and selectivity uncertainties, improving therapeutic outcomes.
Synthetic polymeric ampholyte biomaterials enhance mechanical strength while maintaining hydrophilicity.
Specific Plinabulin polymorphs and hydrochloride salts enhance chemical stability and bioavailability to resolve handling limitations.
Nitrogen-containing polycyclic compounds in the emission layer improve luminous efficiency and service life while reducing driving voltage.
Segmented heteroaryl compounds inhibit aberrant fibroblast growth factor receptor kinase activity to treat deregulated signaling diseases.